Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Clinical trial NCT04626791 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04626791
- Sponsor
- Academic and Community Cancer Research United
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-03
- Primary completion
- 2025-08-03
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.